These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 27379708)

  • 1. A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors.
    Bendell JC; Bauer TM; Lamar R; Joseph M; Penley W; Thompson DS; Spigel DR; Owera R; Lane CM; Earwood C; Burris HA
    Cancer Invest; 2016 Jul; 34(6):265-70. PubMed ID: 27379708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors.
    Bendell JC; Jones SF; Hart L; Pant S; Moyhuddin A; Lane CM; Earwood C; Murphy P; Patton J; Penley WC; Thompson D; Infante JR
    Cancer Invest; 2015; 33(10):477-82. PubMed ID: 26460795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma.
    Seggewiss-Bernhardt R; Bargou RC; Goh YT; Stewart AK; Spencer A; Alegre A; Bladé J; Ottmann OG; Fernandez-Ibarra C; Lu H; Pain S; Akimov M; Iyer SP
    Cancer; 2015 Jul; 121(13):2185-92. PubMed ID: 25809731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer.
    Renouf DJ; Hedley D; Krzyzanowska MK; Schmuck M; Wang L; Moore MJ
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):541-5. PubMed ID: 27422303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial.
    Doi T; Kurokawa Y; Sawaki A; Komatsu Y; Ozaka M; Takahashi T; Naito Y; Ohkubo S; Nishida T
    Eur J Cancer; 2019 Nov; 121():29-39. PubMed ID: 31536852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
    Wagner AJ; Agulnik M; Heinrich MC; Mahadevan D; Riedel RF; von Mehren M; Trent J; Demetri GD; Corless CL; Yule M; Lyons JF; Oganesian A; Keer H
    Eur J Cancer; 2016 Jul; 61():94-101. PubMed ID: 27156227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors.
    Doi T; Onozawa Y; Fuse N; Yoshino T; Yamazaki K; Watanabe J; Akimov M; Robson M; Boku N; Ohtsu A
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):629-36. PubMed ID: 25059319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Johnson ML; Yu HA; Hart EM; Weitner BB; Rademaker AW; Patel JD; Kris MG; Riely GJ
    J Clin Oncol; 2015 May; 33(15):1666-73. PubMed ID: 25870087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of heat shock protein 90 with AUY922 represses tumor growth in a transgenic mouse model of islet cell neoplasms.
    Fendrich V; Wichmann S; Wiese D; Waldmann J; Lauth M; Rexin P; L-Lopez C; Schlitt HJ; Bartsch DK; Lang SA
    Neuroendocrinology; 2014; 100(4):300-9. PubMed ID: 25301256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors.
    Hsueh YS; Chang HH; Chiang NJ; Yen CC; Li CF; Chen LT
    Oncotarget; 2014 Nov; 5(22):11723-36. PubMed ID: 25375091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors.
    Sessa C; Shapiro GI; Bhalla KN; Britten C; Jacks KS; Mita M; Papadimitrakopoulou V; Pluard T; Samuel TA; Akimov M; Quadt C; Fernandez-Ibarra C; Lu H; Bailey S; Chica S; Banerji U
    Clin Cancer Res; 2013 Jul; 19(13):3671-80. PubMed ID: 23757357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.
    Piotrowska Z; Costa DB; Oxnard GR; Huberman M; Gainor JF; Lennes IT; Muzikansky A; Shaw AT; Azzoli CG; Heist RS; Sequist LV
    Ann Oncol; 2018 Oct; 29(10):2092-2097. PubMed ID: 30351341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
    Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
    Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
    Le Cesne A; Blay JY; Bui BN; Bouché O; Adenis A; Domont J; Cioffi A; Ray-Coquard I; Lassau N; Bonvalot S; Moussy A; Kinet JP; Hermine O
    Eur J Cancer; 2010 May; 46(8):1344-51. PubMed ID: 20211560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors.
    Blanke CD; Rankin C; Corless C; Eary JF; Mulder K; Okuno SH; George S; Heinrich M
    Oncologist; 2015 Dec; 20(12):1353-4. PubMed ID: 26576593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma.
    Gaspar N; Sharp SY; Eccles SA; Gowan S; Popov S; Jones C; Pearson A; Vassal G; Workman P
    Mol Cancer Ther; 2010 May; 9(5):1219-33. PubMed ID: 20457619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma.
    Augello G; Emma MR; Cusimano A; Azzolina A; Mongiovì S; Puleio R; Cassata G; Gulino A; Belmonte B; Gramignoli R; Strom SC; McCubrey JA; Montalto G; Cervello M
    Int J Cancer; 2019 May; 144(10):2613-2624. PubMed ID: 30488605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
    Nagengast WB; de Korte MA; Oude Munnink TH; Timmer-Bosscha H; den Dunnen WF; Hollema H; de Jong JR; Jensen MR; Quadt C; Garcia-Echeverria C; van Dongen GA; Lub-de Hooge MN; Schröder CP; de Vries EG
    J Nucl Med; 2010 May; 51(5):761-7. PubMed ID: 20395337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-phenylethynesulphonamide (PFT-μ) enhances the anticancer effect of the novel hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levels.
    Yeramian A; Vea A; Benítez S; Ribera J; Domingo M; Santacana M; Martinez M; Maiques O; Valls J; Dolcet X; Vilella R; Cabiscol E; Matias-Guiu X; Marti RM
    Pigment Cell Melanoma Res; 2016 May; 29(3):352-71. PubMed ID: 26988132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
    Kaiser M; Lamottke B; Mieth M; Jensen MR; Quadt C; Garcia-Echeverria C; Atadja P; Heider U; von Metzler I; Türkmen S; Sezer O
    Eur J Haematol; 2010 Apr; 84(4):337-44. PubMed ID: 20028416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.